Bruton's tyrosine kinase in complex with compound 23

Experimental Data Snapshot

  • Resolution: 1.69 Å
  • R-Value Free: 0.208 
  • R-Value Work: 0.178 
  • R-Value Observed: 0.179 

wwPDB Validation   3D Report Full Report

Ligand Structure Quality Assessment 

This is version 1.2 of the entry. See complete history


Discovery and Preclinical Characterization of BIIB091, a Reversible, Selective BTK Inhibitor for the Treatment of Multiple Sclerosis.

Hopkins, B.T.Bame, E.Bajrami, B.Black, C.Bohnert, T.Boiselle, C.Burdette, D.Burns, J.C.Delva, L.Donaldson, D.Grater, R.Gu, C.Hoemberger, M.Johnson, J.Kapadnis, S.King, K.Lulla, M.Ma, B.Marx, I.Magee, T.Meissner, R.Metrick, C.M.Mingueneau, M.Murugan, P.Otipoby, K.L.Polack, E.Poreci, U.Prince, R.Roach, A.M.Rowbottom, C.Santoro, J.C.Schroeder, P.Tang, H.Tien, E.Zhang, F.Lyssikatos, J.

(2022) J Med Chem 65: 1206-1224

  • DOI: https://doi.org/10.1021/acs.jmedchem.1c00926
  • Primary Citation of Related Structures:  
    7LTY, 7LTZ

  • PubMed Abstract: 

    Multiple Sclerosis is a chronic autoimmune neurodegenerative disorder of the central nervous system (CNS) that is characterized by inflammation, demyelination, and axonal injury leading to permeant disability. In the early stage of MS, inflammation is the primary driver of the disease progression. There remains an unmet need to develop high efficacy therapies with superior safety profiles to prevent the inflammation processes leading to disability. Herein, we describe the discovery of BIIB091, a structurally distinct orthosteric ATP competitive, reversible inhibitor that binds the BTK protein in a DFG-in confirmation designed to sequester Tyr-551, an important phosphorylation site on BTK, into an inactive conformation with excellent affinity. Preclinical studies demonstrated BIB091 to be a high potency molecule with good drug-like properties and a safety/tolerability profile suitable for clinical development as a highly selective, reversible BTKi for treating autoimmune diseases such as MS.

  • Organizational Affiliation

    Research & Development, Biogen, Cambridge, Massachusetts 02142, United States.

Find similar proteins by:  (by identity cutoff)  |  3D Structure
Entity ID: 1
MoleculeChains Sequence LengthOrganismDetailsImage
Isoform BTK-C of Tyrosine-protein kinase BTK267Homo sapiensMutation(s): 0 
UniProt & NIH Common Fund Data Resources
Find proteins for Q06187 (Homo sapiens)
Explore Q06187 
Go to UniProtKB:  Q06187
PHAROS:  Q06187
GTEx:  ENSG00000010671 
Entity Groups  
Sequence Clusters30% Identity50% Identity70% Identity90% Identity95% Identity100% Identity
UniProt GroupQ06187
Sequence Annotations
  • Reference Sequence
Small Molecules
Ligands 2 Unique
IDChains Name / Formula / InChI Key2D Diagram3D Interactions
YD7 (Subject of Investigation/LOI)
Query on YD7

Download Ideal Coordinates CCD File 
B [auth A]~{N}-[(5~{R})-2-[2-[(1-methylpyrazol-4-yl)amino]pyrimidin-4-yl]-6,7,8,9-tetrahydro-5~{H}-benzo[7]annulen-5-yl]-3-propan-2-yloxy-azetidine-1-carboxamide
C26 H33 N7 O2
Query on DMS

Download Ideal Coordinates CCD File 
C2 H6 O S
Experimental Data & Validation

Experimental Data

  • Resolution: 1.69 Å
  • R-Value Free: 0.208 
  • R-Value Work: 0.178 
  • R-Value Observed: 0.179 
  • Space Group: P 21 21 2
Unit Cell:
Length ( Å )Angle ( ˚ )
a = 71.478α = 90
b = 104.178β = 90
c = 38.165γ = 90
Software Package:
Software NamePurpose
XDSdata reduction

Structure Validation

View Full Validation Report

Ligand Structure Quality Assessment 

Entry History 

Deposition Data

Revision History  (Full details and data files)

  • Version 1.0: 2022-01-12
    Type: Initial release
  • Version 1.1: 2022-02-09
    Changes: Database references
  • Version 1.2: 2023-10-18
    Changes: Data collection, Refinement description